Good News for Patients in the New Year

Accentuate the Positive: Good News for Myeloma Patients in 2017

The results of two studies that represent good news for myeloma patients have arrived just in time for the new year, writes IMF Chairman Dr. Brian G.M. Durie in his blog this week. The first study (SWOG 0777) shows that the addition of Velcade® (bortezomib) to a standard two-drug regimen for myeloma patients significantly lengthened the time before their cancer returned, and significantly lengthened their lives. The second study shows the superiority of serum free light chain (sFLC) testing over urine in the response measurement of light-chain myeloma. To read Dr. Durie’s blog, click HERE.

Myeloma Patients Respond to Lenalidomide Maintenance After Autologous Stem Cell Transplant

Patients in the Connect® Multiple Myeloma Registry were treated according to physician discretion with Revlimid® (lenalidomide) maintenance after autologous stem cell transplant (ASCT). In this video, Dr. Rafat Abonour (Indiana University-Simon Cancer Center) explains that this study indicates the quality of life of myeloma patients was not significantly different whether patients were treated with lenalidomide maintenance or not. In the video, Dr. Abonour goes into depth about this very important observation.

 

Best of ASH 2016 Teleconference: What Patients and Caregivers Need to Know

Register now for the FREE Best of ASH 2016 Teleconference to be broadcast on Thursday, January 12 at 4 PM PT / 7 PM ET. Join Dr. Brian G.M. Durie as he discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community. To register, click HERE.

 

IMF Awards Leading Myeloma Researchers with Brian D. Novis Research Grants

On December 3rd, the IMF awarded its 2017 Brian D. Novis Research Grants. The award ceremony was held during the 58th annual meeting of the American Society of Hematology (ASH). The IMF is proud to support these important projects by leading myeloma researchers from institutions around the world. Three Senior Research Grants are being funded at $80,000 each, and five Junior Research Grants are being funded at $50,000 each. For 22 years, the IMF has funded promising clinical investigators in the field of myeloma from around the world through donations from private individuals and IMF Member Fundraisers. To read about this event and the research project clinical investigations, click HERE.

 

The IMF is Proud to Announce the New and Improved Myeloma Matrix 2.0: Clinical Trial Search

This comprehensive and easy-to-use clinical trial resource has been vastly improved. Myeloma Matrix 2.0: Smart Search is an important tool for the entire myeloma community, and is easy to navigate. The new Myeloma Matrix helps patients gain knowledge about myeloma drugs currently under development and tracks them through all phases from Pre-Clinical (laboratory-only) to FDA approval. Search this tool HERE.

 


We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb